Anal Cancer Prevention in High-Risk Categories of Men Who Have Sex With Men

Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexMale
Age35+
SponsorBispebjerg Hospital

About this trial

The incidence of anal cancer is increasing, particularly among high-risk groups such as men who have sex with men (MSM), especially those living with HIV. The lack of comprehensive screening programs results in delayed diagnosis and higher mortality.

This project aims to establish a screening program for anal cancer in high-risk populations, with a specific focus on those most at risk. Using a prospective study design, the project will assess the effectiveness of early detection and prevention strategies to potentially reduce cancer incidence and improve survival rates. If an HPV-based screening method proves effective, it would serve as a potential implemention for high-risk groups in Denmark, further enhancing early detection and prevention efforts.

This study represents the first large-scale, prospective screening initiative for anal cancer in Denmark,specifically targeting MSM. It introduces a novel approach to cancer prevention in this population by building on research in other cancers and adapting it to anal cancer and its specific risk factors.

The project is a collaboration between clinical practitioners and academic researchers, ensuring that practical clinical insights guide the research and that research findings are rapidly translated into clinical practice. This partnership will enhance both the quality of the research and its direct application in healthcare.

The project is expected to lead to earlier diagnosis of anal cancer, reduced morbidity and mortality among high-risk populations, and the establishment of a screening model that can be applied nationwide. This could significantly reduce the overall healthcare burden associated with late-stage anal cancer and improve patient outcomes across Denmark.

Eligibility criteria

Qualifiers

MSM with HIV

HIV-negative MSMonPrEP

Age >=35 years

Written and orally informed consent in English or Danish

Disqualifiers

Previous anal cancer

Rectum extirpation (of any cause)

Unwilling to have HRA performed

Inflammatory bowel disease

Trial design

Treatments tested in this trial

  • High resolution anoscopy

Treatment groups

700 Participants
are divided into 1 treatment group

Locations

This trial has no locations

Sponsors and collaborators

Bispebjerg Hospital

Lead sponsor

Vejle Hospital

Collaborator

Aarhus University Hospital

Collaborator

Odense University Hospital

Collaborator

Hvidovre University Hospital

Collaborator

Rigshospitalet, Denmark

Collaborator